Vascular diseases (Paris, France)最新文献

{"title":"Porcelain aorta and markedly elevated lipoprotein(a): A signature phenotype of genetically driven pan-arterial calcific atherosclerosis.","authors":"Camille Zamperini, Elena-Mihaela Cordeanu, Dominique Stephan","doi":"10.1016/j.vasdi.2026.06.001","DOIUrl":"10.1016/j.vasdi.2026.06.001","url":null,"abstract":"","PeriodicalId":520901,"journal":{"name":"Vascular diseases (Paris, France)","volume":" ","pages":"199-200"},"PeriodicalIF":0.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148371827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Symptomatic carotid web management: A prospective single-center cohort study.","authors":"Donia Soulimani, Ruben Tamazyan, Maxime Raux, Julien Adam, Ulrique Michon-Pasturel, Mathieu Zuber, Alexandra Yannoutsos","doi":"10.1016/j.vasdi.2026.05.002","DOIUrl":"10.1016/j.vasdi.2026.05.002","url":null,"abstract":"<p><strong>Introduction: </strong>Carotid web (CaW), a focal intimal dysplasia, is a potential cause of embolic ischemic stroke (IS). The optimal therapeutic approach for symptomatic CaW remains unclear.</p><p><strong>Methodology: </strong>Since January 2016, patients hospitalized for IS with an ipsilateral CaW, identified during etiological workup, are prospectively included in this ongoing single-center observational cohort study.</p><p><strong>Results: </strong>Until April 2024, 32 patients (59% men; mean age 48±7.5 years; mean NIHSS score 8±6) were included. Seven patients (22%) had a history of prior IS. Thrombolysis and/or thrombectomy were performed in 15 patients (47%). During follow-up, recurrent IS occurred in 6 patients (19%), while on antiplatelet therapy (APT), with a median recurrence time of 39 days (IQR 8-144). Etiological workup identified CaW on CT angiography in 30 patients (94%) and on arteriography in 17 patients (53%). CaW was suspected on ultrasonography in 26 patients (81%) and confirmed with a second imaging modality. CaW was identified as the primary etiological diagnosis in 29 patients. Alternative diagnoses in 3 patients included atrial fibrillation (n=1), patent foramen ovale (n=1) and inherited thrombophilia (protein S deficiency) associated with a suspected right-to-left pulmonary shunt on transesophageal echocardiography (n=1). Among the 29 patients with symptomatic CaW, anticoagulation was prescribed in 21 cases (72%). Antiplatelet therapy (APT) was prescribed in 8 patients (28%), primarily due to hemorrhagic transformation in 7 of them. Carotid endarterectomy (26 patients) or angioplasty with stent placement (3 patients) was performed within a median of 28 days (IQR 14-84) with no major complications (2 spontaneously resolving laryngeal edema). Histopathological analysis of 19 endarterectomy specimens revealed associated thrombus in 5 cases (26%). Postoperatively, all patients were prescribed APT. No ischemic recurrence or death was reported during a mean follow-up of 24±20 months.</p><p><strong>Conclusion: </strong>Medical management alone for symptomatic CaW was associated with IS recurrence. Combined interventional approach effectively prevented cerebrovascular events. Further randomized studies are needed to determine the optimal therapeutic approach, particularly the preferred revascularization strategy.</p>","PeriodicalId":520901,"journal":{"name":"Vascular diseases (Paris, France)","volume":" ","pages":"165-171"},"PeriodicalIF":0.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148020548","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cancer treatment-related ischemic arterial events: Focus on peripheral arterial disease and cerebrovascular events.","authors":"Gilles Pernod, Gabrielle Sarlon-Bartoli, Marie Antoinette Sevestre","doi":"10.1016/j.vasdi.2026.02.006","DOIUrl":"10.1016/j.vasdi.2026.02.006","url":null,"abstract":"<p><p>Cancer therapies, including VEGF inhibitors, BCR-ABL tyrosine kinase inhibitors (TKIs), immune checkpoint inhibitors (ICIs), multiple myeloma and hormonal therapies, are associated with an increased risk of arterial thrombotic events (ATEs). While most studies have focused on myocardial and cerebral ischemia, this review highlights the underreported peripheral arterial complications, peripheral arterial disease (PAD) and cerebrovascular events. VEGF inhibitors, such as bevacizumab and VEGFR-TKIs (e.g., sorafenib, sunitinib), significantly elevate the risk of ATEs, with hypertension and proteinuria as common comorbidities. BCR-ABL-TKIs, especially nilotinib and ponatinib, are linked to rapid-onset PAD, even in patients without prior cardiovascular risk factors. ICIs triple the progression of aortic plaque volume, increasing the risk of ischemic stroke and myocardial infarction. Hormonal therapies, including tamoxifen and androgen deprivation therapy, also contribute to ATEs through metabolic and vascular mechanisms. Radiotherapy further exacerbates arterial disease, particularly carotid stenosis and iliofemoral atherosclerosis, in head, neck, and pelvic cancer survivors. Monitoring and prevention strategies, such as regular cardiovascular risk assessments, lipid management, and arterial ultrasound surveillance, are critical for high risk patients. Multidisciplinary onco-vascular teams are essential to mitigate these risks and optimize patient outcomes.</p>","PeriodicalId":520901,"journal":{"name":"Vascular diseases (Paris, France)","volume":" ","pages":"137-143"},"PeriodicalIF":0.0,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147322765","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Management of hypertension in primary care: A cross-sectional study of general practitioner practices in Seine-Saint-Denis, France.","authors":"Nawel Sekhri, Robin Dhôte, Sylvain Le Jeune, Antonio Morabito","doi":"10.1016/j.vasdi.2026.02.008","DOIUrl":"10.1016/j.vasdi.2026.02.008","url":null,"abstract":"<p><strong>Background: </strong>Hypertension remains poorly controlled in France despite available treatments. Therapeutic inertia and non-adherence of physicians to guidelines contribute to this situation.</p><p><strong>Objective: </strong>This study aimed to evaluate general practitioners' (GPs) practices in the initial management of hypertension in Seine-Saint-Denis, a socioeconomically disadvantaged French department.</p><p><strong>Methods: </strong>We conducted a cross-sectional study using an online self-administered questionnaire from March to May 2025. Fifty-three GPs completed the survey regarding their diagnostic, therapeutic, and follow-up practices in the management of hypertensive patients.</p><p><strong>Results: </strong>Most physicians (66%) used the recommended 140/90mmHg office threshold for hypertension diagnosis, and 94% confirmed diagnosis with ambulatory measurements. However, only 55% used cardiovascular risk scores to assess prognosis, and key recommended diagnostic investigations (electrocardiogram: 43%; urinary albumin: 47%) were underperformed. Initial antihypertensive therapy was predominantly monotherapy (83%) whereas dual therapy was prescribed in 17% of patients, and blood pressure targets were frequently set higher than recommended. Notable variations in practice were observed according to physician age, gender, and years of experience.</p><p><strong>Conclusion: </strong>Although GPs in Seine-Saint-Denis generally adhere to basic hypertension management principles, significant gaps remain in cardiovascular risk assessment, initial workup completeness, and timely treatment intensification. Targeted interventions are needed to enhance guideline implementation in this vulnerable territory.</p>","PeriodicalId":520901,"journal":{"name":"Vascular diseases (Paris, France)","volume":" ","pages":"128-132"},"PeriodicalIF":0.0,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147535617","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Supraceliac aorta as antegrade inflow for chronic mesenteric ischemia is a viable option in high-surgical-risk patients.","authors":"Georges Ghorayeb, Didier Plissonnier","doi":"10.1016/j.vasdi.2026.02.005","DOIUrl":"10.1016/j.vasdi.2026.02.005","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the feasibility and early outcomes of antegrade visceral revascularization using the supraceliac aorta as inflow in high-surgical-risk patients with chronic mesenteric ischemia (CMI) refractory to endovascular treatment.</p><p><strong>Patients and methods: </strong>A retrospective review was conducted from 2015 to 2022 including patients who underwent supraceliac to visceral bypass for symptomatic CMI after failed endovascular revascularization. All patients were deemed high risk based on the American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP) score. Bypasses were performed through a transperitoneal midline approach using partial aortic cross-clamping. The primary outcome was 30-day mortality. Secondary outcomes included postoperative complications, intensive care unit (ICU) stay, and long-term survival.</p><p><strong>Results: </strong>Twelve patients (median age 75 years; 6 women) underwent surgery. Bypasses targeted the superior mesenteric artery alone (n=10) or combined with the common hepatic artery (n=2), using prosthetic (n=12) or venous grafts (n=2). Median aortic clamping time was 24minutes. In this series there was no 30-day mortality. Postoperative complications were limited to one case of pneumonia and one transient acute kidney injury. Median ICU stay was 2 days. All patients experienced symptom resolution. At a median follow-up of 45 months, 11 of 12 patients were alive.</p><p><strong>Conclusion: </strong>Antegrade revascularization from the supraceliac aorta via midline laparotomy is feasible in selected high-surgical-risk patients with CMI. This approach could be considered when endovascular options fail.</p>","PeriodicalId":520901,"journal":{"name":"Vascular diseases (Paris, France)","volume":" ","pages":"123-127"},"PeriodicalIF":0.0,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147322771","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Physician knowledge and practices regarding cardiovascular risk assessment and LDL-cholesterol targets determination: A monocentric cross-sectional survey.","authors":"Giovanni Orecchio, Sylvain Le Jeune, Antonio Morabito","doi":"10.1016/j.vasdi.2026.02.007","DOIUrl":"10.1016/j.vasdi.2026.02.007","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Cardiovascular diseases (CVD) remain the leading global cause of mortality. Approximately 50% of the CVD burden is attributable to five modifiable risk factors, including dyslipidemia. Effective management of low-density lipoprotein cholesterol (LDL-C) through accurate cardiovascular (CV) risk stratification is fundamental to prevention. However, in daily practice, significant variability exists in how clinicians assess CV risk and determine appropriate LDL-C targets, potentially leading to suboptimal patient care.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;This cross-sectional survey aimed to evaluate the consistency and alignment with current guidelines of CV risk assessment and LDL-C target selection among clinicians working at Avicenne University Hospital, Assistance publique-Hôpitaux de Paris (Bobigny, France), when presented with diverse and challenging clinical scenarios, that formal risk calculation tools cannot assess.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;Between September and November 2025, a questionnaire-based cross-sectional survey was conducted at Avicenne University Hospital. Thirty doctors and residents from five departments (internal medicine, vascular-thoracic surgery, cardiology, geriatrics, endocrinology) participated. They were presented with six clinical vignettes designed to probe CV risk assessment in complex contexts such as heart failure, atherosclerotic cardiovascular disease (ASCVD), recurrent events, and chronic kidney disease. Responses were categorized into CV risk groups (low to extreme) based on the proposed LDL-C target, in accordance with the 2025 ESC/EAS dyslipidemia guidelines. Responses without a specific target were classified as \"No category.\"&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Analysis revealed significant heterogeneity in responses. The \"no category\" response was the most frequent overall (29.4% of all answers), indicating substantial clinician uncertainty. Key discrepancies from guidelines included: high uncertainty (43.3% \"no category\") in assigning risk after heart failure; underestimation of risk in confirmed ASCVD (most answers were moderate or high risk, not very high); reluctance to use the Extreme-risk category (&lt;40mg/dL) for recurrent events; and insufficient recognition of moderate CKD as a High-risk factor. Vascular surgeons most frequently gave \"no category\" answers (54.8% of their responses) however, there was no statistically significant difference in the proportion of \"no category\" responses across departments (P=0.093).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;This survey identified a notable gap between guideline recommendations and clinical practice in CV risk assessment at the hospital level. Clinicians demonstrated a tendency to underestimate risk in key areas like ASCVD and CKD, and exhibited significant uncertainty in complex scenarios such as heart failure and recurrent events. These findings underscore the need for targeted educational initiatives and strategies to promote","PeriodicalId":520901,"journal":{"name":"Vascular diseases (Paris, France)","volume":" ","pages":"115-122"},"PeriodicalIF":0.0,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147322768","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Carotid and abdominal aortic pseudoaneurysms secondary to traditional massages.","authors":"Fanomezantsoa Raherinantenaina, Mahefa Mijoro Henintsoa, Eric Olsen Rakotomalala, Andriamihaja Jean Claude Rakotoarisoa, Hery Nirina Rakoto Ratsimba, Toky Mamin'ny Aina Rajaonanahary","doi":"10.1016/j.vasdi.2026.04.002","DOIUrl":"10.1016/j.vasdi.2026.04.002","url":null,"abstract":"","PeriodicalId":520901,"journal":{"name":"Vascular diseases (Paris, France)","volume":" ","pages":"159-162"},"PeriodicalIF":0.0,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147857883","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Thalidomide for high-flow arteriovenous malformations: A case report and comprehensive literature review.","authors":"Alexis Cardenas, Thomas Foret, Alexandra Fournel, Eve Puzenat, Patricia Costa","doi":"10.1016/j.vasdi.2026.04.001","DOIUrl":"10.1016/j.vasdi.2026.04.001","url":null,"abstract":"<p><p>High-flow arteriovenous malformations (AVM) are uncommon vascular anomalies that may lead to significant morbidity, and management becomes challenging when curative interventions are not feasible. Here, we report a 46-year-old man with a refractory upper-limb AVM who experienced rapid improvement in pain and function under thalidomide 50mg/day, with a reduction in shunt flow (3.0 to 2.2 L/min). Treatment was discontinued after six months due to non-severe adverse effects, while benefits persisted at one year. A literature search identified few case reports, all showing consistent symptomatic improvement and mainly dose-dependent, reversible toxicity. Thalidomide could represent a useful adjunct for selected high-flow AVM resistant to standard therapy, although controlled studies are required.</p>","PeriodicalId":520901,"journal":{"name":"Vascular diseases (Paris, France)","volume":" ","pages":"155-158"},"PeriodicalIF":0.0,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147795947","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is lymphedema an inflammatory disease?","authors":"Stéphane Vignes","doi":"10.1016/j.vasdi.2026.03.001","DOIUrl":"10.1016/j.vasdi.2026.03.001","url":null,"abstract":"","PeriodicalId":520901,"journal":{"name":"Vascular diseases (Paris, France)","volume":" ","pages":"113-114"},"PeriodicalIF":0.0,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147826349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Contribution of sclerotherapy to the management of chronic venous insufficiency at the Abidjan Heart Institute: A preliminary study.","authors":"Kouassi Florent Koffi, Esaïe K Soya, Janvier M Midago, Christelle Gbassi, Martin Luther Takam, Kohen B A Kapena, Christophe K Konin, Isabelle Quéré","doi":"10.1016/j.vasdi.2026.02.001","DOIUrl":"10.1016/j.vasdi.2026.02.001","url":null,"abstract":"<p><strong>Introduction: </strong>Sclerotherapy is a minimally invasive technique that offers an effective alternative to surgical management of chronic venous insufficiency. Despite its growing use worldwide, its application remains underreported in Sub-Saharan Africa. This preliminary study aims to evaluate the clinical outcomes and therapeutic value of sclerotherapy in patients with superficial chronic venous disease at Abidjan Heart Institute.</p><p><strong>Methods: </strong>A retrospective, descriptive and analytical study was conducted from November 2023 to July 2025. All patients who underwent sclerotherapy for chronic venous insufficiency were included. A total of 64 cases were reviewed.</p><p><strong>Results: </strong>Among the 64 patients, women accounted for 56.2% of the cohort, although men presented with more advanced and symptomatic disease, including venous claudication, and ulceration. The great saphenous vein was the most frequently treated segment (60.9%). Symptomatic relief was achieved in 85.9% of patients. Duplex ultrasound confirmed successful venous occlusion in all cases. A palpable indurated cord was observed in 100% of patients, consistent with expected post-sclerotherapy changes. Ulcer healing in 3 months was encouraging (31.25%). Sclerotherapy should only be performed under ultrasound guidance to improve accuracy and safety. In addition, no significant complications were observed during the six-month follow-up period. Minor events included hyperpigmentation and transient pain, managed conservatively.</p><p><strong>Conclusion: </strong>Sclerotherapy proves to be a safe, effective, and well-accepted therapeutic option in the Ivorian context. In the absence of endovenous thermal ablation facilities, it offers a credible alternative to conventional venous surgery, particularly in resource-limited settings.</p>","PeriodicalId":520901,"journal":{"name":"Vascular diseases (Paris, France)","volume":" ","pages":"133-136"},"PeriodicalIF":0.0,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147322769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}